Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd

₹ 828 -3.37%
21 Sep - close price
About

Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries.[1]

Key Points

Product Offerings[1]
Company offers a wide range of pharma products/ drugs in the form of oral solids, liquids, topical products, respiratory MDI/DPI and complex injectables & biologics. It is primarily focused on therapy areas of dermatology, respiratory and oncology.

  • Market Cap 23,355 Cr.
  • Current Price 828
  • High / Low 880 / 364
  • Stock P/E 15.9
  • Book Value 634
  • Dividend Yield 0.30 %
  • ROCE 10.9 %
  • ROE 9.12 %
  • Face Value 1.00

Pros

  • Company's working capital requirements have reduced from 95.2 days to 52.2 days

Cons

  • The company has delivered a poor sales growth of 8.29% over past five years.
  • Company has a low return on equity of 10.2% over last 3 years.
  • Dividend payout has been low at 4.55% of profits over last 3 years

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023
1,683 2,062 1,972 1,850 2,142 2,181 2,033 1,786 1,912 2,208 2,161 1,939 2,144
1,174 1,567 1,442 1,494 1,585 1,721 1,523 1,624 1,478 1,826 1,723 1,721 1,659
Operating Profit 509 495 530 356 557 460 510 162 434 382 439 218 485
OPM % 30% 24% 27% 19% 26% 21% 25% 9% 23% 17% 20% 11% 23%
163 63 127 117 138 511 217 179 347 317 252 -425 18
Interest 60 60 83 63 59 53 50 74 40 52 56 59 62
Depreciation 36 37 41 37 37 40 41 42 45 46 46 47 49
Profit before tax 576 462 533 373 598 878 637 225 696 601 589 -313 392
Tax % 20% 13% 17% 8% 18% 14% 14% 9% 29% 30% 27% 56% 31%
462 403 442 342 489 754 549 206 493 423 430 -137 272
EPS in Rs 16.39 14.28 15.68 12.11 17.34 26.73 19.44 7.29 17.46 15.00 15.26 -4.87 9.63
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
1,565 1,949 2,301 5,086 6,115 7,989 5,520 6,305 6,713 7,568 8,142 8,221 8,453
1,253 1,617 1,805 3,618 4,349 5,089 4,417 4,977 5,407 5,676 6,453 6,748 6,929
Operating Profit 311 332 496 1,467 1,766 2,900 1,103 1,328 1,305 1,892 1,689 1,473 1,524
OPM % 20% 17% 22% 29% 29% 36% 20% 21% 19% 25% 21% 18% 18%
55 116 67 -86 116 -89 326 954 624 469 1,044 490 161
Interest 61 44 31 30 36 153 191 224 256 266 236 207 229
Depreciation 21 25 30 119 100 105 96 106 139 151 160 184 188
Profit before tax 284 380 502 1,232 1,747 2,553 1,143 1,952 1,535 1,944 2,337 1,572 1,268
Tax % 7% -2% 14% 18% 15% 16% 11% 17% 12% 15% 15% 23%
265 386 434 1,008 1,484 2,141 1,014 1,622 1,355 1,649 1,998 1,209 988
EPS in Rs 9.81 14.25 15.99 37.14 52.60 75.86 35.95 57.49 48.01 58.46 70.80 42.84 35.02
Dividend Payout % 20% 14% 12% 5% 4% 3% 6% 3% 5% 4% 4% 6%
Compounded Sales Growth
10 Years: 15%
5 Years: 8%
3 Years: 7%
TTM: 7%
Compounded Profit Growth
10 Years: 15%
5 Years: 9%
3 Years: 6%
TTM: -10%
Stock Price CAGR
10 Years: 5%
5 Years: 5%
3 Years: 22%
1 Year: 113%
Return on Equity
10 Years: 14%
5 Years: 11%
3 Years: 10%
Last Year: 9%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
27 27 27 27 28 28 28 28 28 28 28 28
Reserves 2,159 2,496 2,879 4,925 7,338 9,408 10,363 11,914 13,198 14,781 16,710 17,849
489 581 353 410 787 2,777 2,981 3,134 3,574 3,704 3,738 3,221
494 782 970 2,289 1,960 1,787 1,892 2,066 2,152 2,104 2,438 3,487
Total Liabilities 3,169 3,886 4,230 7,651 10,113 14,001 15,265 17,143 18,952 20,618 22,914 24,586
224 276 449 1,231 1,438 1,596 1,699 1,413 1,612 1,722 1,752 1,746
CWIP 69 172 83 294 276 271 420 286 200 131 109 172
Investments 1,083 1,294 1,409 1,660 1,858 1,867 3,213 3,269 4,714 6,990 8,559 10,334
1,793 2,143 2,289 4,466 6,541 10,267 9,933 12,174 12,426 11,774 12,494 12,334
Total Assets 3,169 3,886 4,230 7,651 10,113 14,001 15,265 17,143 18,952 20,618 22,914 24,586

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
195 253 114 145 355 878 1,124 2,490 1,579 1,243 1,216 1,474
602 -119 211 -176 -1,545 -2,580 -1,137 -2,256 -1,607 -1,235 -897 -432
-780 -14 -385 -32 1,223 1,879 -62 -155 -139 -81 -305 -978
Net Cash Flow 16 120 -60 -64 32 177 -75 79 -168 -73 14 64

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 84 104 180 175 182 177 253 121 100 120 120 111
Inventory Days 151 128 126 161 182 172 195 141 115 94 100 117
Days Payable 232 287 337 343 306 221 273 258 217 201 205 225
Cash Conversion Cycle 2 -55 -31 -6 59 129 175 4 -3 14 16 3
Working Capital Days 66 -2 98 104 155 179 252 168 130 141 92 52
ROCE % 12% 15% 17% 33% 26% 29% 10% 13% 11% 12% 11% 11%

Shareholding Pattern

Numbers in percentages

Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023
46.63% 46.63% 46.63% 46.63% 46.65% 46.65% 46.65% 46.65% 46.65% 46.65% 46.65% 46.65%
25.79% 26.48% 25.84% 26.82% 25.93% 24.18% 24.12% 24.23% 23.14% 23.19% 22.47% 25.51%
4.46% 9.43% 9.16% 9.73% 9.03% 10.86% 10.96% 10.50% 10.90% 10.69% 10.40% 9.10%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.04% 0.04% 0.04% 0.04%
23.13% 17.46% 18.38% 16.82% 18.40% 18.31% 18.27% 18.63% 19.27% 19.45% 20.46% 18.70%
No. of Shareholders 2,63,0602,36,7302,50,8512,75,8013,29,8703,17,3833,10,5163,12,4733,13,5403,00,1062,85,4612,36,908

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls